To scroll text in this page
Thank you for your support and interest.
Astellas Pharma Inc., to fulfill its business philosophy to "Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products," is actively engaged in business as an R&D-driven global pharmaceutical company.
The pharmaceutical industry continued to face severe business conditions as demonstrated by the progression of government policies to restrain medical expenditures and the tightening up of NDA reviews, particularly in the developed countries. Operating in this environment, Astellas strove to gain a very precise and accurate understanding of the changing market environment and respond to these changes with greater speed and flexibility so that it may continue to create new drugs and remain competitive in the global market.
In 2006, foreseeing the changes that would occur in the market environment, we formulated "VISION 2015" to establish a vision of the company that we want Astellas to be in 2015. Our business model under this plan is to continuously create new drugs in several therapeutic areas where current therapeutic options are unsatisfactory and establish a superior competitive position in the global market, in other words, we chose to become a "Global Category Leader (GCL)." In May 2010, we formulated the "2014 Mid-Term Management Plan," a five-year plan outlining concrete strategies to realize our GCL ambitions and we are presently very active in working to achieve the plan's goals.
It is precisely our GCL ambitions in this plan that provides us with the confidence that this business model will enable us to achieve our business philosophy, our raison d'être, of "Contributing toward improving the health of people around the world through the provision on innovative and reliable pharmaceutical products."
Through positive investment over the span of several years, Astellas has realized the basic strategies essential to underpin this business model. We have "strengthened the research and technology base," "enhanced our development pipeline of new drug candidates" and "expanded globally to achieve a four-region business platform consisting of Japan, the Americas, Europe and Asia." These strategies are now our "strengths." By advancing even more powerfully with our growth strategies that leverage our strengths, we firmly believe Astellas will develop an identity as a globally competitive company. In my new role, I feel enormous responsibility and have immense determination to realize our vision.
I hope that we will continue to enjoy your collective support and understanding.